KY-1044 (Alomfilimab; SAR 445256) is a fully humanized IgG1 monoclonal antibody that selectively targets the inducible costimulatory receptor (ICOS). This antibody is designed to deplete ICOS-high expressing cells through the mechanism of antibody-dependent cellular cytotoxicity (ADCC), facilitated by the engagement of Fc??RIIIa receptors. Additionally, KY-1044 serves as a costimulatory molecule for cells expressing lower levels of ICOS, such as CD8+ effector T cells, via Fc??R-dependent clustering. This dual functionality allows KY-1044 to modulate the differential expression of ICOS across various T-cell subtypes, thereby enhancing the intratumoral immune contexture and promoting an effective antitumor immune response. KY-1044 is primarily researched for its potential therapeutic applications in oncology, focusing on its ability to manipulate immune responses within the tumor microenvironment.
KY-1044 (Alomfilimab; SAR 445256) is a fully humanized IgG1 monoclonal antibody that selectively targets the inducible costimulatory receptor (ICOS). This antibody is designed to deplete ICOS-high expressing cells through the mechanism of antibody-dependent cellular cytotoxicity (ADCC), facilitated by the engagement of Fc??RIIIa receptors. Additionally, KY-1044 serves as a costimulatory molecule for cells expressing lower levels of ICOS, such as CD8+ effector T cells, via Fc??R-dependent clustering. This dual functionality allows KY-1044 to modulate the differential expression of ICOS across various T-cell subtypes, thereby enhancing the intratumoral immune contexture and promoting an effective antitumor immune response. KY-1044 is primarily researched for its potential therapeutic applications in oncology, focusing on its ability to manipulate immune responses within the tumor microenvironment.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
